Regulations.gov document
Reference 2 - U.S. Food and Drug Administration. FDA is temporarily exercising enforcement…
Supporting & Related Material · FDA-2022-P-2425 · posted Apr 25, 2024
Key facts
| Document ID | FDA-2022-P-2425-0005 |
|---|---|
| Title | Reference 2 - U.S. Food and Drug Administration. FDA is temporarily exercising enforcement discretion with respect to certain Clozapine REMS program requirements to ensure continuity of care for patients taking clozapine [Internet]. 2021 December 2. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-temporarily-exercising-enforcement-discretion-respect-certain-clozapine-rem |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2022-P-2425 |
| Posted | Apr 25, 2024 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: